Live Q&A: Best of UEG Week 2022 twitter.com/i/broadcasts/1…
#GITwitter #MondayNightIBD
⭐️⭐️⭐️NOW - Best of #IBD @ #UEGWeek Q&A w all-star faculty ⭐️⭐️⭐️
In collab w @my_ueg
TWEET your❓❓❓below ⬇️
Supported by edu grants from @abbvie & BMS⭐️⭐️⭐️
Join now w/ @CharlieMuz @DCharabaty @Iris_Dotan @MRegueiroMD
📲Tweet your❓below
3/#MondayNightIBD #UEGWeek
📍Where are you in your career?
4/#MondayNightIBD #UEGWeek
🇺🇸🇬🇧🇮🇱🇦🇹🇨🇦🇫🇷🇩🇪🇮🇹🇨🇳🇯🇵🇦🇺🇬🇹🇲🇽🇧🇷
📍Where are you joining from?
5/#MondayNightIBD #UEGWeek
👇#PostConvo #IBDPoll 1️⃣
🟢In the True North open-label extension, the findings indicated that approx 1/2 the pts who failed to achieve a CR after 10wks of ozanimod induction tx benefitted from which of the following:
6/#MondayNightIBD #UEGWeek
👇#PostConvo #IBDPoll 2⃣
🟢Which drug combo were given in the Ph2a VEGA study to show the potential of dual inhibition of IL-23 & TNFα to more effectively induce CR & remission in pts w mod-sev UC?
7/#MondayNightIBD #UEGWeek
👇#PostConvo #IBDPoll 3⃣
🟢Which of the following PRO questionnaires assesses pt fatigue using a 13-item tool & 5-point scale, where a ⬆️higher score indicates a better pt outcome?
8/#MondayNightIBD #UEGWeek
👇#PostConvo #IBDPoll 4⃣
🟢The U-ACHIEVE Maintenance study, looked @ pts w UC who responded to induction tx w upadacitinib @ 8wks
Which tx group led to greater clinical remission per adapted Mayo score at wk 52 compared to PBO?
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.